GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.
GLP-1 drugs show meaningful weight and blood sugar benefits in children with obesity and diabetes, offering options as childhood obesity rates climb.
GLP-1 receptor agonists demonstrate significant efficacy and acceptable tolerability in pediatric obesity and diabetes across multiple RCTs and meta-analyses. The systematic review is timely given surging pediatric obesity rates and expanding regulatory approvals for GLP-1 RAs in children.
What the study was
- Study design
- Systematic review of RCTs and meta-analyses
- Population
- Children aged 6 to <18 years with obesity or T2DM; 7 RCTs, 6 meta-analyses, n≈901
- Sample size
- 901
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Diabetes research and clinical practice
Why it surfaced
Comprehensive systematic review of GLP-1 RAs in pediatric obesity/T2DM; high clinical relevance amid expanding approvals; timely with global pediatric obesity epidemic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.